Leqembi Iqlik® for initiation treatment launched in the US

Contributed by: PR Newswire

Tags

BIOARCTIC-Leqembi

More Like This

FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease

Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.

Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status

US FDA approves Leqembi® IQKLIK™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease

Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing

Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025

Leqembi approved for the treatment of Alzheimer's disease in Israel